BEAM News and Press, Beam Therapeutics Inc. From 11/01/23

2023-11-01 05:40:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood, the brilliant mind behind ARK Invest , is known for her unique ability to spot disruptive trends in stocks. Her investment strategies have made waves in the financial world, an...

2023-10-31 19:09:02 ET A multimillion-dollar deal in the healthcare industry announced on Tuesday led to share price pops for two of the three parties involved. Shares of Beam Therapeutics (NASDAQ: BEAM) and Verve Therapeutics (NASDAQ: VERV) shot up 11% and 28%, respectively...

2023-10-31 12:46:31 ET More on Eli Lilly Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated Eli Lilly: Do Not Chase This Stock Over The Cliff ...

2023-10-31 10:00:00 ET On Oct. 19, the early-stage gene-editing biotech Beam Therapeutics (NASDAQ: BEAM) announced it would be slashing its workforce by 100 employees, or around 20% of its total, while also refocusing its pipeline on the programs it assumes have the best chance of e...

2023-10-31 06:38:32 ET More on Beam, Eli Lilly, etc. Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore Beam: Opportunity Based On SCD Data Readout In 2024 Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underes...

CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Eli Lilly and Company (Lilly) has agreed to acquire certain rights under Beam’s amended c...

2023-10-30 09:18:15 ET Beam Therapeutics (NASDAQ: BEAM) stands out among gene-editing stocks because the company uses base editing as a more precise method than the first generation of CRISPR gene editing. The thought is that, instead of cutting both strands of DNA, Beam trims singl...

Single Dose of BEAM-301 Restored Clinically Meaningful Endpoints in In Vivo Rodent Disease Models Out to at Least One Year Company Plans to Submit U.S. Investigational New Drug (IND) Application for BEAM-301 in the First Half of 2024 CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWS...

2023-10-25 05:50:00 ET Cathie Wood doesn't mind going against the grain. In the past, she's made big bets with her Ark Invest funds that haven't been in sync with the conventional wisdom. And she appears to be doing it again with Beam Therapeutics (NASDAQ: BEAM) . Shares of Beam...

2023-10-24 08:05:14 ET More on Beam, CRISPR, etc. Beam: Opportunity Based On SCD Data Readout In 2024 Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy Editas Medicine: A Mispriced Contender In The Gene Editing Arena Beam extend...